Drug Trial Radar · NCT05918692
A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Jul 26, 2023
Primary completion
Jan 1, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Biomea Fusion Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
Conditions
- Acute Myeloid Leukemia
Interventions
BMF-500Drug
Investigational Product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of BMF-500 by incidence of Treatment Emergent Adverse Events (TEAEs).Time frame: At the end of each 28 Day cycle for a maximum of 32 cycles
- Evaluate the safety and tolerability of BMF-500 by incidence of Serious Adverse Events (SAEs).Time frame: At the end of each 28 Day cycle for a maximum of 32 cycles
- Determine the recommended Phase 2 Dose (RP2D) of BMF-500.Time frame: At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period
- Determine the recommended Phase 2 Dose (RP2D) of BMF-500.Time frame: At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period
- Determine the recommended Phase 2 Dose (RP2D) of BMF-500.Time frame: At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period
- Determine the recommended Phase 2 Dose (RP2D) of BMF-500.Time frame: At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona
City of Hope National Medical Center
Duarte, California
University of California, San Francisco
San Francisco, California
Colorado Blood Cancer Institute
Denver, Colorado
Mayo Clinic
Jacksonville, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
University of Kentucky - Markey Cancer Center
Lexington, Kentucky
Mayo Clinic
Rochester, Minnesota
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Texas Oncology-PA USOR
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists
Gainesville, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.